Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2CNS 2Myeloid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Lung Neoplasms 1Histiocytosis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

etoposide phosphate 1cc-486 1Sirolimus 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Panitumumab 1Molecular Diagnostic Techniques 1Megestrol Acetate 1Injections 1Immunotherapy 1IFL protocol 1Gemcitabine 1Fentanyl 1Etoposide 1Drug Therapy 1Cyproheptadine 1Cyclophosphamide 1Cetuximab 1Celecoxib 1Biological Therapy 1Azacitidine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × IFL protocol × Myeloid × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡